

























































































































34 2.65	 [1.72-4.23])	 as	 independent	 risk	 factors	 for	postoperative	 complications.	Patients	undergoing	
35 
36 major		 surgery		 for		upper		gastrointestinal		cancer		experienced		 twice		 the		 rate		of		 complications	
37 








































7 develop	 life	 threatening	 complications.	 Postoperative	 complications	 increase	 treatment	
9 costs,[11,12]	 and	 reduce	 both	 life	 expectancy	 and	 quality	 of	 life	 at	 a	 societal	 level.[3,14]	Whilst	
10 
11 technical	 errors	 are	 unusual	 during	 surgery	 and	 anaesthesia,	 poor	 patient	outcomes	 persist	 for	 a	
12 



























43 complications	and	death	after	 in-patient	elective	surgery	at	a	global	 level,	and	to	describe	current	
44 
45 standards	of	postoperative	care.[19]	 ISOS	included	a	prospective	sub-group	analysis	 to	describe	 in	
46 







































25 The	 inclusion	 criteria	 were	 all	 adult	 patients	 (age	 ≥18	 years)	 undergoing	 elective	 surgery	 with	 a	
26 
27 planned	 overnight	 stay	 in	 hospital.	 Patients	 undergoing	 emergency	 surgery,	 day-case	 surgery	 or	
28 
29 radiological	 procedures	 were	 excluded.	We	 aimed	 to	 recruit	 as	 many	 hospitals	 and	 countries	 as	
30 
31 possible	and	asked	 investigators	 in	those	hospitals	 to	enrol	all	eligible	patients.	No	 formal	sample	
32 size		calculation		was		performed.		Only		hospitals		returning		valid		data		describing		≥20		patients	and	33 





































2 predefined	criteria	and	graded	according	 to	 the	Clavien-Dindo	classification.[21,22]	The	secondary	
3 outcome	measure	was	 in-hospital	mortality.	 Process	measures	were	 admission	 directly	 to	 critical	
































41 describing	 baseline	 risk	 factors	were	missing	 for	 a	 very	 small	 proportion	 of	 patients	 [451/44	 814	
42 











































































55 In		 the		 initial		 univariable		 regression		 analysis,		 age		 (OR		 1.03		 [1.02-1.04]),		 American		 Society		 of	






































27 Using	the	World	Bank	classification,	eight	were	classed	as	 low	or	middle-income	countries	 (Brazil,	























































16 a		complication		died	before		hospital		discharge.		Patients		undergoing	major	cancer		surgery		are			 at	17 



















39 the	 lower	observed	 complication	 rates	 in	our	 series.[28]	 Infectious	 complications	 such	as	 surgical	
41 site		infections	and	pneumonia		remain	commonplace,		and		are	associated	with		 prolonged		hospital	
42 





































11 definitive		 surgical		 treatment.		A		 recent		Australian		study		did		not		demonstrate		any		 correlation	
12 between	age	and	long-term	survival,	even	though	postoperative	complications	were	more	frequent	13 




18 surgery		 amongst		 elderly		 patients.		 ASA		 score		 has		 been		 highlighted		 as		 a		 strong		 predictor		 of	
19 postoperative	complications.[32]	It	is	interesting	to	note	that	a	relatively	large	proportion	of	patients	






27 oesophagectomy		 falling		 into		ASA		 III		 and		 IV		 categories.[33]		Recent		 recommendations		 for		 the	
28 treatment			of			upper			gastrointestinal			cancer			recommend			careful			patient			selection			based		 on	29 
30 physiological	 reserve	 and	pre-existing	 co-morbid	disease.[34,35]	One	 in	 six	 patients	 in	 this	 cohort	
31 
32 were		 admitted		 to		 a		 critical		 care		 unit		 immediately		 after		 surgery,		 half		 of		whom		 experienced	
33 













49 very		 simple		data		 set		 consisting		 primarily		 of		 categorical		 variables		 to		 aid		data		 collection		 and	
50 
51 minimising		empty		data		fields.		Patient-level		variables		were		selected	on		the		basis		that		they	were	







































































































































43 The	 authors	 are	 happy	 to	 consider	 data	 sharing	 requests	 from	 bona	 fide	 researchers.	 Participant	












































































































































































































of	Anesthesiologists	 physical	 status	 score;	 COPD,	 chronic	 obstructive	 pulmonary	 disease.	We	 compared	 patients	













Age	 56	(16)	 61	(15)	 55	(16)*	
Male	 1034	(48.3%)	 271	(54.5%)	 761	(46.3%)*	
Female	 1108	(51.7%)	 227	(45.6%)	 881	(53.7%)*	
Smoker	 397	(18.8%)	 101	(20.3%)	 295	(18.3%)	
Black	ethnicity	 190	(9.0%)	 32	(6.5%)	 158	(9.8%)*	
ASA	score	  
I	 337	(15.8%)	 43	(8.7%)	 294	(17.9%)*	
II	 1104	(51.7%)	 219	(44.1%)	 884	(54.0%)*	
III	 631	(29.5%)	 206	(41.4%)	 424	(25.9%)*	
IV	 65	(3.0%)	 29	(5.8%)	 36	(2.2%)*	
Severity	of	surgery	  
Minor	 297	(13.9%)	 30	(6.0%)	 267	(16.3%)*	
Intermediate	 857	(40.0%)	 145	(29.1%)	 712	(43.4%)*	
Major	 985	(46.0%)	 322	(64.7%)	 661	(40.3%)*	
Chronic	disease	  
Ischaemic	heart	disease	 189	(8.9%)	 59	(11.8%)	 130	(8.0%)*	
Heart	failure	 83	(3.9%)	 28	(5.6%)	 55	(3.4%)*	
Diabetes	mellitus	 309	(14.5%)	 79	(15.9%)	 229	(14.0%)	
Cirrhosis	 27	(1.3%)	 11	(2.2%)	 16	(1.0%)*	
Surgery	for	Cancer	 750	(35.1%)	 269	(54.0%)	 479	(31.7%)*	
Metastatic	cancer	 140	(6.6%)	 54	(10.8%)	 86	(5.3%)*	
Stroke	 73	(3.4%)	 22	(4.4%)	 51	(3.1%)	
COPD/Asthma	 240	(11.3%)	 62	(12.4%)	 178	(10.9%)	
Other	chronic	disease	 926	(43.4%)	 259	(52.0%)	 630	(38.6%)*	
Blood	test	results	  
Haemoglobin	(g/dL)	 12.7	(2.1)	 12.3	(2.2)	 12.9	(2.1)*	
Creatinine	(µmol/L)	 79	(53)	 84	(54)	 77	(52)*	
Sodium	(mmol/L)	 139	(6)	 139	(8)	 140	(5)	
Leucocytes	(x10-9/mm3)	 7.7	(4.6)	 8.4	(7.6)	 7.4	(2.9)	


























Pneumonia	N	(%)	 31	(1.4%)	 46	(2.1%)	 0	(0%)	 21	(1.0%)	 10	(0.5%)	 108	(5.0%)	
Superficial	surgical	site	
N	(%)	 42	(2.0%)	 28	(1.3%)	 5	(0.2%)	 3	(0.1%)	 1	(0.1%)	 79	(3.7%)	
Body	cavity	N	(%)	 24	(1.2%)	 19	(0.9%)	 0	(0%)	 19	(0.9%)	 2	(0.1%)	 64	(3.0%)	
Deep	surgical	site	N	(%)	 12	(0.6%)	 25	(1.2%)	 0	(0%)	 12	(0.6%)	 4	(0.2%)	 53	(2.5%)	
Bloodstream	N	(%)	 11	(0.5%)	 14	(0.7%)	 1	(0.1%)	 9	(0.4%)	 6	(0.3%)	 41	(1.9%)	
Urinary	tract	N	(%)	 12	(0.6%)	 14	(0.7%)	 0	(0%)	 1	(0.1%)	 4	(0.2%)	 31	(1.4%)	
Cardiovascular	
Arrhythmia	N	(%)	 35	(1.6%)	 36	(1.7%)	 3	(0.1%)	 8	(0.4%)	 6	(0.3%)	 88	(4.1%)	
Pulmonary	oedema	N	
(%)	 14	(0.7%)	 4	(0.2%)	 0	(0%)	 3	(0.1%)	 1	(0.1%)	 22	(1.0%)	
Cardiac	arrest	N	(%)	 -	 -	 -	 5	(0.2%)	 9	(0.5%)	 14	(0.7%)	
Myocardial	infarction	N	
(%)	 1	(0.1%)	 2	(0.1%)	 0	(0%)	 3	(0.1%)	 2	(0.1%)	 8	(0.4%)	
Pulmonary	embolism	N	
(%)	 1	(0.1%)	 3	(0.1%)	 0	(0%)	 2	(0.1%)	 0	(0%)	 6	(0.3%)	
Stroke	N	(%)	 1	(0.1%)	 0	(0%)	 0	(0%)	 2	(0.1%)	 3	(0.2%)	 6	(0.3%)	
Other	complications	
Post-operative	bleeding	
N	(%)	 -	 56	(2.6%)	 0	(0%)	 11	(0.5%)	 14	(0.7%)	 81	(3.8%)	
Acute	kidney	injury	N	
(%)	 24	(1.1%)	 22	(1.0%)	 0	(0%)	 10	 12	(0.6%)	 68	(3.2%)	
Anastomotic	leakage	N	
(%)	 12	(0.6%)	 12	(0.6%)	 5	(0.2%)	 20	(0.9%)	 6	(0.3%)	 55	(2.6%)	
Gastro-intestinal	
bleeding	N	(%)	 23	(1.1%)	 11	(0.5%)	 0	(0%)	 1	(0.1%)	 4	(0.2%)	 39	(1.8%)	
ARDS	N	(%)	 8	(0.4%)	 8	(0.4%)	 0	(0%)	 3	(0.1%)	 5	(0.2%)	 24	(1.1%)	
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